SCHEMBL3717348

SCHEMBL3717348

Cc1nc(C(=O)C(N)C(=O)O)c(O)c2c(-c3ccc(OC(F)(F)F)cc3)noc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.39
DPP7 Q9UHL4 1/20 0.39
KIT P10721 2/20 0.37
KDR P35968 2/20 0.37
FLT3 P36888 2/20 0.37
ABL1 P00519 1/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
CSF1R P07333 1/20 0.37
LYN P07948 1/20 0.37
SRC P12931 1/20 0.37
FLT1 P17948 1/20 0.37
FLT4 P35916 1/20 0.37
BLK P51451 1/20 0.37
SCN10A Q9Y5Y9 1/20 0.36
PPARD Q03181 3/20 0.35
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
DHODH Q02127 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3711503 0.88 PTGS2 (0.40) GPBAR1PTGS2
SCHEMBL3721279 0.86 EGLN1 (0.39) GPBAR1SMN1; SMN2PTGS2
SCHEMBL3717749 0.84 GPBAR1 (0.38) DPP4DPP7DHODHGPBAR1
SCHEMBL2775078 0.83 CACNA2D1 (0.41) KITKDRFLT3ABL1LCK
SCHEMBL3656841 0.83 SCN10A (0.37) DPP4DPP7KITKDRFLT3
SCHEMBL2777688 0.81 EGLN1 (0.47)
SCHEMBL3714165 0.80 TPH1 (0.40) GPBAR1SMN1; SMN2PTGS2
SCHEMBL3656839 0.79 EGLN1 (0.45)
SCHEMBL2776342 0.74 MLYCD (0.41) DPP4DPP7KITKDRFLT3
SCHEMBL3715648 0.73 NR4A2 (0.44) FLT3NPSR1SMN1; SMN2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227475-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS Fibrogen, Inc. (US) 2010-09-15 EP disclosed
WO-2009073669-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2009-06-11 WO disclosed